Answers are grounded in this paper and cite their sources.
Invasive fungal diseases remain a significant cause of patient morbidity and mortality. Improvement in clinical outcomes have been the result of progress in risk stratification, diagnostics, adjunctive care, antifungal therapy, and/or prophylaxis. Yet significant challenges remain, requiring the development of novel treatment strategies. Outcome evaluation in most mycology clinical trials is currently based on consensus criteria published in 2008. However, advances in diagnosis and management of various mycoses and the ever-expanding population of patients at risk necessitate a revision and refinement of these criteria. Appropriate categorization of antifungal treatment response is crucial in assessing the effects of new therapeutic interventions. An international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened to update the current outcome evaluation criteria. The panel achieved consensus on updated guidelines for assessing treatment responses and defining study outcomes in clinical trials of aspergillosis and other mold diseases, invasive candidiasis, cryptococcosis, and dimorphic fungi in both adults and children. This summary manuscript provides details on the methods, outlines key changes in the criteria, and discusses the next steps and areas for future research.
No takes yet. Share an insight, caveat, or question.
Hoenigl et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: